内容由MediCom Oncology提供。所有播客内容(包括剧集、图形和播客描述)均由 MediCom Oncology 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Player FM -播客应用
使用Player FM应用程序离线!
使用Player FM应用程序离线!
值得一听的播客
赞助
“That's taxpayer’s money that is going to support research and development and pilot projects to develop a food system that is based on environmental destruction and greed and disregard for animals, fish, and any of the other marine mammals that might be around it.” - Andrianna Natsoulas Andrianna Natsoulas is the campaign director for Don't Cage Our Oceans, an organization that exists to keep our oceans free from industrial fish farms. Offshore finfish farming is the mass cultivation of finfish in marine waters, in underwater or floating net pens, pods, and cages. Offshore finfish farms are factory farms that harm public health, the environment, and local communities and economies that rely on the ocean and its resources. Don’t Cage Our Oceans are a coalition of diverse organizations working together to stop the development of offshore finfish farming in the United States through federal law, policies, and coalition building. And, although it is not yet happening, right now the US Administration and Congress are promoting this kind of farming, which would be nothing short of disastrous for the oceans, the planet and the people and animals who live here. dontcageouroceans.org…
Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant IDH2
Manage episode 184110665 series 1375096
内容由MediCom Oncology提供。所有播客内容(包括剧集、图形和播客描述)均由 MediCom Oncology 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Dr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.
…
continue reading
53集单集
Manage episode 184110665 series 1375096
内容由MediCom Oncology提供。所有播客内容(包括剧集、图形和播客描述)均由 MediCom Oncology 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Dr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.
…
continue reading
53集单集
Wszystkie odcinki
×M
MediCom Oncology Clinical Pearls Podcasts

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.
M
MediCom Oncology Clinical Pearls Podcasts

1 How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance 3:58
In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).
M
MediCom Oncology Clinical Pearls Podcasts

Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.
M
MediCom Oncology Clinical Pearls Podcasts

Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.
M
MediCom Oncology Clinical Pearls Podcasts

1 What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics? 2:40
Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.
M
MediCom Oncology Clinical Pearls Podcasts

Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.
M
MediCom Oncology Clinical Pearls Podcasts

Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.
M
MediCom Oncology Clinical Pearls Podcasts

1 What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma? 3:01
Listen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.
M
MediCom Oncology Clinical Pearls Podcasts

Listen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.
欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。